Roche Pharmaceutical Development and Sales Overview
Vabysmo (faricimab, RG7716)
Bispecific antibody to simultaneously bind Ang-2 and VEGF-A
Indication
Macular edema (ME) secondary to branch retinal vein occlusion (RVO)
Phase/study
# of patients
Design
"
Primary endpoint
Status
CT Identifier
Phase III
BALATON
N=570
"
ARM A: Faricimab, q4w/PTI
ARM B: Aflibercept, q4w
Change from baseline in BCVA at week 24
FPI Q1 2021
Recruitment completed Q1 2022
NCT04740905
PTI-Personalized Treatment Interval; BCVA-best corrected visual acuity; Ang-2-Angiopoietin-2; VEGF-Vascular endothelial growth factor
"
ā
Roche
Macular edema (ME) secondary to central retinal vein occlusion (RVO)
ARM A: Faricimab, q4w/PTI
ARM B: Aflibercept, q4w
Phase III
COMINO
N=750
"
Change from baseline in BCVA at week 24
FPI Q1 2021
Recruitment completed Q1 2022
NCT04740931
101
OphthalmologyView entire presentation